INKT - NASDAQ
MiNK Therapeutics, Inc.
$12.76
+1.4%MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
At a Glance
Live SnapshotMiNK Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Cash Flow Quality Insight
Deteriorating cash generation: Both declining FCF and weak conversion rate signal fundamental challenges. Investigate margin pressure, rising costs, or working capital issues.
MiNK Therapeutics, Inc. Cash Flow Statement
INKT • NASDAQ
| MiNK Therapeutics, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||
-12.5B | -10.8M | -22.5M | -28M | -30.2M | -16.2M | -23.8M | |
181.7M | 215.4K | 204.6K | 121.7K | 78K | 55.1K | 36.8K | |
2.7B | 1.8M | 3.9M | 3M | 1.7M | 87.8K | 219.6K | |
3.7B | -1.3M | -266.8K | -2.8M | 11.8M | 8.1M | 4.5M | |
3.3M | 459.7K | 2.9M | 8.8M | 3.7M | -324.9K | 4.1M | |
-5.9B | -9.6M | -15.8M | -18.9M | -12.8M | -8.3M | -14.9M | |
INVESTING ACTIVITIES | |||||||
(0.0) | (0.0) | -73.6K | -250K | -249K | -95.2K | -426.5K | |
(0.0) | (0.0) | -73.6K | -250K | -249K | -95.2K | -426.5K | |
FINANCING ACTIVITIES | |||||||
14.9M | 5.8M | -477.6K | -157.2K | 39.8M | 901.0 | 0.0 | |
0.0 | 5M | 0.0 | 0.0 | 9.5M | 11.1M | 11.4M | |
(0.0) | (0.0) | -477.6K | -157.2K | (0.0) | (0.0) | (0.0) | |
14.7B | 20K | 70.5K | 1.6K | 150.0 | 0.0 | 0.0 | |
14.7B | 10.8M | -407.2K | -155.6K | 49.3M | 11.1M | 11.4M | |
CASH FLOW SUMMARY | |||||||
-13.4M | -54.7K | -25.3K | 19.4K | 16.9K | -281.2K | -122.1K | |
8.8B | 1.2M | -16.3M | -19.3M | 36.2M | 2.4M | -4.1M | |
4.6B | 3.4M | 19.6M | 38.9M | 2.7M | 299K | 4.4M | |
13.4B | 4.6M | 3.4M | 19.6M | 38.9M | 2.7M | 299K | |
-5.9B | -9.6M | -15.8M | -19.1M | -13.1M | -8.4M | -15.4M |
SEC Filings
INKT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 15, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 15, 2026 | May 15, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | June 17, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 31, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 31, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 27, 2026 | March 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 19, 2026 | March 13, 2026 | 2026 | |
8-K 8-K 2025 N/A | January 02, 2026 | December 29, 2025 | 2025 | |
S-3/A S-3/A (Amended) N/A | December 10, 2025 | December 10, 2025 | ||
8-K 8-K 2025 N/A | December 08, 2025 | November 14, 2025 | 2025 |
Related Guides
Continue your INKT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.